Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

In Vivo Efficacy of AAV5-Mediated Gene Therapy for Alpha-1 Antitrypsin Deficiency

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

In Vivo Efficacy of AAV5-Mediated Gene Therapy for Alpha-1 Antitrypsin Deficiency

In Vivo Efficacy Studies for AAV5-Mediated Alpha-1 Antitrypsin Deficiency Therapy

CELL & GENE | RNA | BIOLOGICS

    What is the primary objective of an AAV5 efficacy study for AATD?

    The primary objective is to demonstrate sustained, therapeutic levels of human alpha-1 antitrypsin (hAAT) protein expression and associated functional correction following vector administration in a relevant in vivo model. The study is designed to generate a robust data package supporting dose selection and predicting clinical benefit.

    Why is AAV5 a common vector choice for AATD gene therapy?

    The adeno-associated virus serotype 5 (AAV5) exhibits a favorable tropism for certain target tissues, such as skeletal muscle, which can serve as a biofactory for secreting the AAT protein into circulation. This serotype has a well-documented clinical safety and efficacy profile for this application.

    What are the key bioanalytical endpoints for these preclinical studies?

    Key endpoints include quantifying circulating hAAT protein levels over time, determining vector genome copy number (VCN) in target and non-target tissues, running functional assays to confirm protein activity (e.g., neutrophil elastase inhibition), and conducting comprehensive immunogenicity assessments.

    How does Franklin Biolabs ensure data integrity for IND submission?

    All pivotal nonclinical studies are executed within a GxP-compliant framework. We utilize validated bioanalytical methods, maintain rigorous quality system oversight, and ensure complete data traceability to generate regulatory-compliant data packages ready for submission.

Successful development of AAV5-mediated gene therapies for Alpha-1 Antitrypsin Deficiency (AATD) depends on preclinical in vivo models that rigorously demonstrate sustained, functional protein expression. Long-term clinical data confirms that a single administration can achieve durable therapeutic benefit, establishing a clear translational path. Franklin Biolabs designs and executes these complex pharmacology studies, generating the pivotal efficacy and biodistribution data required to support an accelerated 18-24 month IND timeline.

Designing AAV5 Efficacy Programs for AATD

A primary challenge in AATD gene therapy is proving the stability and biological activity of the expressed protein over an extended duration. The design of an in vivo pharmacology study must prioritize longitudinal analysis. This approach validates the therapeutic hypothesis and informs dose-selection strategy for first-in-human trials.

Insights from long-term clinical follow-up studies (PMID: 28408179) have shown that sustained, multi-year protein expression is achievable from a single vector administration. This work underscores the viability of using tissues like skeletal muscle as a production depot for circulating AAT, suggesting the approach is both tolerogenic and effective. Our study designs incorporate these principles, focusing on generating data that directly addresses questions of durability and functional correction.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Core Bioanalytical Endpoints for AATD Studies

A comprehensive in vivo study for an AAV5-AATD candidate requires a multi-faceted analytical strategy to build a complete dataset for regulatory review.

  • hAAT Protein Quantification: Validated immunoassays (e.g., ELISA) are used to measure circulating levels of the human AAT protein over the full duration of the study.

  • Vector Biodistribution: Quantitative PCR (qPCR) assays determine vector genome copy numbers, confirming delivery to the intended target tissues and evaluating distribution to non-target tissues.

  • Functional Activity: Bioassays are employed to confirm that the expressed hAAT protein is functionally active and capable of inhibiting its target, neutrophil elastase.

  • Immunogenicity Assessment: We monitor for humoral immune responses against both the AAV5 capsid and the hAAT transgene protein to characterize the host response profile.

  • Histology: Microscopic examination of key tissues confirms transgene expression at the cellular level and provides valuable safety information regarding local tissue response.

Animal Welfare and Program Execution

[VIDEO: FBL-VID-09-Approved_enhanced_responsibility_clip_long.mp4]

All animal research programs at Franklin Biolabs are governed by the principles of the 3Rs (Reduction, Refinement, and Replacement). Our studies are conducted at facilities that are fully accredited by AAALAC International and operate in compliance with USDA guidelines.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

From Preclinical Data to IND Submission

The data generated from these pharmacology and efficacy studies forms the foundation of the IND application. Our GxP-compliant operations, conducted in a >100,000 sq ft facility, ensure that every dataset is generated with the regulatory endpoint in mind. This rigorous approach has supported a 100% IND success rate for our partners’ programs since 2019 (with the Franklin Biolabs brand itself launching in 2024).

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

Our team works directly with sponsors to compile and interpret the data, delivering an IND-enabling package that clearly communicates the therapy’s mechanism of action, efficacy, and safety profile.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities